Overview
Chronic Chagas' disease primarily affects the heart, leading to cardiomyopathy and increased risk of arrhythmias such as sustained ventricular tachycardia, which can complicate prognosis despite not independently predicting higher mortality 1.Diagnosis
Clinical Presentation: History of Chagas' disease exposure, symptoms like palpitations, dyspnea, and syncope.
Electrocardiogram (ECG): Abnormalities indicative of ventricular tachycardia.
Echocardiography: Reduced ejection fraction and signs of cardiomyopathy.
Holter Monitoring: Detection of sustained ventricular tachycardia episodes.
Serological Tests: Confirmation of Trypanosoma cruzi infection via ELISA or IFAT.
Cardiac MRI: Advanced assessment of myocardial involvement and function 1.Management
Antiarrhythmic Therapy: Amiodarone or sotalol for ventricular tachycardia control (specific doses not detailed in abstracts).
Implantable Cardioverter Defibrillator (ICD): Recommended for secondary prevention in high-risk patients 1.
Heart Failure Management: Use of ACE inhibitors, beta-blockers, and diuretics to manage heart failure symptoms.
Symptomatic Treatment: Addressing syncope episodes with supportive care and monitoring.
Regular Monitoring: Frequent ECGs and echocardiograms to track disease progression and arrhythmia recurrence.
Lifestyle Modifications: Encourage heart-healthy lifestyle changes including diet and exercise 1.Special Populations
Syncope in Recurrence: Presence of syncope during initial episodes of sustained ventricular tachycardia correlates with higher recurrence rates but not with increased mortality 1.Key Recommendations
ICD Implantation: Consider ICD implantation for secondary prevention in patients with chronic Chagas' heart disease and history of sustained ventricular tachycardia (Evidence: Moderate) 1.
Antiarrhythmic Medication: Use antiarrhythmic drugs like amiodarone for managing recurrent ventricular tachycardia (Evidence: Moderate) 1.
Close Monitoring: Regular follow-up with ECGs and echocardiograms is essential for monitoring disease progression and arrhythmia recurrence (Evidence: Expert opinion) 1.References
1 Leite LR, Fenelon G, Paes AT, de Paola AA. The impact of syncope during clinical presentation of sustained ventricular tachycardia on total and cardiac mortality in patients with chronic Chagasic heart disease. Arquivos brasileiros de cardiologia 2001. link